07.02.2025 15:08:51
|
Neurocrine Biosciences Reports Mixed Q4
Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly. Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives.Source: Neurocrine Biosciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. SG&A = Selling, general, and administrative expensesContinue readingWeiter zum vollständigen Artikel bei MotleyFool
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Q4 Inc Registered Shs Unitarymehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Q4 Inc Registered Shs Unitarymehr Analysen
Aktien in diesem Artikel
Neurocrine Biosciences Inc. | 111,85 | -0,09% |
|